Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti — Clinical Trial Site

83 Registered trials

42 Currently recruiting

Organisation

Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti

Location

Bucharest, Romania

Identifier

ORG-100044237

Address

Soseaua Fundeni 252, 022328, Romania

Departments

#98350011: Oncology
3200: Medical Oncology II Department, Radiotherapy I Department
6101: Oncology
6102:Oncologie Medicala I
93150004: Clinica Radioterapie II
93150011: Medica Oncology I
Departament Clinic Oncologie Medicala II
Departamentul de Oncologie Medicala
Department of Medical Oncology
Medical
Medical Oncology
Medical Oncology department
Medical Oncology Department 2
Medical Oncology I
Medical Oncology II
Medical Oncology II Department
Medical Oncology II Department, Radiotherapy I Department
Medical Oncology II Section
Medical Oncology II, Radiotherapy I
Oncologie
Oncologie Medicala
Oncologie Medicala II
Oncology
Pediatric Oncology
Phase 1 Unit, Medical Oncology II, Radiotherapy I
Phase I Unit, Medical Oncology II, Radiotherapy I
Radiotherapy Clinical Department II
Radiotherapy Department II
ROU009: Oncology
Sectia Oncologie Pediatrica

Clinical trials at this site (83)

Search interface

A Phase 3 study of NBTXR3 with or without cetuximab in LA-HNSCC Recruiting

2024-520386-31-00 Locally Advanced Head & Neck Squamous Cell Carcinoma 5 2025-09-22
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting

2024-517780-24-00 Lung Cancer 5 2025-09-18
A Study of Navlimetostat (BMS986504) in Participants with Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer with Homozygous MTAP… Recruiting

2024-519814-29-00 Advanced or Metastatic Non-small Cell Lung Cancer 4 2025-09-12
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting

2024-515884-69-00 Extensive Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-07-16
A Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy in Participants with Non-s… Recruiting

2024-513682-40-01 Non-squamous (NSQ), Stage IV or Recurrent Non-small Cel 5 2025-07-04
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting

2024-515698-85-00 Locally Advanced or Metastatic Non-small Cell Lung Canc 5 2025-06-12
An open-label, pharmacokinetic, safety, and efficacy study (Part I, single cycle) and double-blind, efficacy, non inferiority, and safety st… Recruiting

2024-514321-39-00 Chemotherapy-induced nausea and vomiting 10 2025-05-06
A Clinical Trial for Patients with Advanced Cancers Recruiting

2024-515020-36-00 Advanced Solid tumour 9 2025-02-24
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
Phase 1, open-label, multicenter, dose escalation study of SRG-1505 as monotherapy in subjects with mature b-cell malignancies Recruiting

2023-505204-34-00 Mature B-Cell Neoplasm, Non-Hodgkin Lymphoma, Diffuse l 1 2024-12-30
A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in … Recruiting

2024-510900-34-00 Solid Tumors 1 2024-11-22
A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc… Recruiting

2024-511319-91-00 Advanced non-small cell lung cancer with HER2 (ERBB2) m 5 2024-10-23
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment Recruiting

2024-516291-16-00 Acute myeloid lymphoma (AML), myelodysplastic syndrome 3 2021-10-26
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects wi… Recruiting

2024-514010-12-00 Advanced Malignancies 1 2020-12-03
Pan tumor Roll Over Study Recruiting

2023-506914-32-00 Pan tumor 4 2020-05-05
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or… Recruiting

2023-507149-27-00 Chemotherapy-induced Thrombocytopenia in Adult subjects 5 2019-11-04
A Study of Subcutaneous Nivolumab plus Intravenous Ipilimumab and Chemotherapy in Participants with Previously Untreated Metastatic or Recur… Ended

2024-520108-25-00 Non-small cell lung cancer (NSCLC) 4 2025-11-05
BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part… Ended

2024-515740-23-00 Extensive-Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-03-25